Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

06/13/2012 | 08:52am US/Eastern
   By Victoria Stilwell 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at

Recommend :
React to this article
Latest news on MERCK & CO., INC.
2d ago AstraZeneca steps up push into cancer immunotherapy
2d ago MERCK : Bayer continues positive business development; Sales growth in all subgr..
2d ago MERCK : CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Merck's..
2d ago MERCK : Second quarter of 2014: Bayer continues positive business development
3d ago ALLERGAN : "Sustained Release Intraocular Implants and Methods for Treating Ocul..
3d ago MERCK : Study Results from Merck & Company in the Area of Nephrology Reported [R..
3d ago MERCK : Data from Merck & Company Advance Knowledge in Translational Medicine (H..
4d ago MERCK : U.S. stocks dip as sanctions hit Russia over Ukraine; Dow falls 0.41%
4d ago Wall Street ends down; Twitter rallies after-hours
4d agoDJPfizer Still Looking to Buy; Results Beat Views -- 2nd Update
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
Merck _ Co., Inc. : Income Statement Evolution
More Financials
Dynamic quotes